Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
RDY 
Dr. Reddy’s Laboratories Ltd ADR (RDY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/31/2025: RDY (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $14.61
1 Year Target Price $14.61
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 18.41% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 12/31/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 11.74B USD | Price to earnings Ratio 18 | 1Y Target Price 14.61 |
Price to earnings Ratio 18 | 1Y Target Price 14.61 | ||
Volume (30-day avg) 4 | Beta 0.34 | 52 Weeks Range 12.18 - 16.07 | Updated Date 01/1/2026 |
52 Weeks Range 12.18 - 16.07 | Updated Date 01/1/2026 | ||
Dividends yield (FY) 0.65% | Basic EPS (TTM) 0.78 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 17.13% | Operating Margin (TTM) 18.45% |
Management Effectiveness
Return on Assets (TTM) 8.78% | Return on Equity (TTM) 17.36% |
Valuation
Trailing PE 18 | Forward PE 22.27 | Enterprise Value 11662249603 | Price to Sales(TTM) 0.03 |
Enterprise Value 11662249603 | Price to Sales(TTM) 0.03 | ||
Enterprise Value to Revenue 3.06 | Enterprise Value to EBITDA 10.63 | Shares Outstanding 832523765 | Shares Floating 600310158 |
Shares Outstanding 832523765 | Shares Floating 600310158 | ||
Percent Insiders - | Percent Institutions 13.94 |
Upturn AI SWOT
Dr. Reddy’s Laboratories Ltd ADR
Company Overview
History and Background
Dr. Reddy's Laboratories Ltd was founded in 1984 by Dr. Kallam Anji Reddy. It began as a manufacturer of active pharmaceutical ingredients (APIs) for the Indian market. Key milestones include its expansion into finished dosage forms, its listing on Indian stock exchanges, and its ADR listing on the New York Stock Exchange (NYSE). The company has grown into a global pharmaceutical enterprise with a focus on affordable and innovative medicines.
Core Business Areas
- Global Generics: This segment focuses on developing, manufacturing, and marketing a wide range of generic pharmaceutical products across various therapeutic areas. It includes branded generics and over-the-counter (OTC) products in emerging markets and developed markets.
- Pharmaceutical Services and Active Ingredients (PSAI): This segment provides API manufacturing services to other pharmaceutical companies and also sells APIs to external customers. It is a significant contributor to the company's revenue and leverages its strong R&D and manufacturing capabilities.
- Proprietary Products: This segment focuses on developing differentiated formulations and novel drug delivery systems. It aims to address unmet medical needs and create value through innovation, often targeting chronic diseases.
- Biosimilars: Dr. Reddy's is actively involved in the development and commercialization of biosimilars, which are highly similar versions of approved biologic medicines. This segment targets complex biological treatments and offers more affordable alternatives.
Leadership and Structure
Dr. Reddy's Laboratories is led by a professional management team with a Board of Directors overseeing its strategic direction. The company operates through various business units aligned with its core segments, with a global presence and regional operational structures.
Top Products and Market Share
Key Offerings
- Sunitinib Malate (Sutentu00ae generic): A generic version of an oncology drug used to treat certain types of kidney cancer and gastrointestinal stromal tumors. Competitors include original brand manufacturer Pfizer and other generic API and formulation players.
- Ritonavir Tablets: An antiretroviral medication used to treat HIV/AIDS. Competitors include original brand manufacturers and other generic pharmaceutical companies globally.
- Gabapentin: An anticonvulsant and analgesic medication used to treat epilepsy and neuropathic pain. This is a widely available generic with numerous competitors globally.
- Various Cardiovascular and Anti-diabetic medications: Dr. Reddy's offers a broad portfolio of generic drugs in these high-volume therapeutic areas, facing intense competition from both large multinational and smaller generic manufacturers.
Market Dynamics
Industry Overview
The global pharmaceutical industry is characterized by intense competition, stringent regulatory environments, and a growing demand for affordable medicines. The generics market continues to be driven by patent expirations and government healthcare policies promoting cost containment. Biosimilars are a rapidly growing segment, offering significant opportunities due to the high cost of biologics.
Positioning
Dr. Reddy's Laboratories is a significant player in the global pharmaceutical market, particularly in emerging economies and the generics space. Its competitive advantages lie in its strong R&D capabilities, robust manufacturing infrastructure, diversified product portfolio, and established market presence in key geographies.
Total Addressable Market (TAM)
The global pharmaceutical market is valued in trillions of dollars, with the generics segment comprising a substantial portion. Dr. Reddy's is positioned to capture a growing share of this market by focusing on product development, strategic partnerships, and expanding its geographic reach. The company is well-positioned to leverage the increasing demand for affordable healthcare solutions.
Upturn SWOT Analysis
Strengths
- Strong R&D capabilities and a focus on innovation.
- Diversified product portfolio across multiple therapeutic areas.
- Established global manufacturing and supply chain infrastructure.
- Significant presence in emerging markets.
- Experienced leadership team and skilled workforce.
Weaknesses
- Reliance on a few key products for revenue.
- Exposure to price erosion in the highly competitive generics market.
- Regulatory challenges and compliance requirements in different geographies.
- Potential for delays in product approvals.
Opportunities
- Growth in biosimilars market.
- Expansion into new geographic markets.
- Strategic acquisitions and partnerships.
- Increasing demand for affordable healthcare globally.
- Leveraging digital technologies for R&D and commercialization.
Threats
- Intense competition from global and local players.
- Changes in regulatory policies and pricing pressures.
- Patent expirations and increased generic competition for branded drugs.
- Economic downturns affecting healthcare spending.
- Geopolitical risks and supply chain disruptions.
Competitors and Market Share
Key Competitors
- Sun Pharmaceutical Industries Ltd. (India, not a direct US stock listing)
- Cipla Ltd. (India, not a direct US stock listing)
- Lupin Limited (India, not a direct US stock listing)
- Teva Pharmaceutical Industries Ltd. (TEVA)
- Viatris Inc. (VTRS)
- AbbVie Inc. (ABBV) - for some biologics/biosimilars
- Amgen Inc. (AMGN) - for some biologics/biosimilars
Competitive Landscape
Dr. Reddy's faces intense competition from established generic manufacturers and innovative pharmaceutical companies. Its advantages include a strong focus on R&D, a diversified product pipeline, and a significant presence in emerging markets. However, it must navigate pricing pressures and regulatory hurdles to maintain its competitive edge.
Growth Trajectory and Initiatives
Historical Growth: Dr. Reddy's has demonstrated consistent historical growth through organic expansion, strategic product launches, and market penetration in key regions. Its focus on complex generics and biosimilars has been a significant driver of this growth.
Future Projections: Future projections are typically based on analyst estimates and the company's strategic roadmap, focusing on pipeline development, market expansion, and potential M&A activities. Growth is expected to be driven by its established generics business and its investments in higher-margin areas like biosimilars and proprietary products.
Recent Initiatives: Recent initiatives include expanding its biosimilar portfolio, entering into strategic partnerships for product development and commercialization, and investing in digital transformation to enhance R&D and manufacturing efficiency. The company also continues to focus on strengthening its presence in North America and Europe.
Summary
Dr. Reddy's Laboratories Ltd ADR is a well-established global pharmaceutical company with a strong foundation in generics and a growing presence in biosimilars. Its robust R&D, diversified portfolio, and emerging market strength are key advantages. However, it faces intense competition and pricing pressures in the generics space, necessitating continued innovation and strategic expansion. Focusing on high-growth areas and efficient operations will be crucial for sustained success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Annual Reports
- Financial News Websites (e.g., Reuters, Bloomberg)
- Market Research Reports
- Analyst Reports
Disclaimers:
This information is for informational purposes only and does not constitute financial advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dr. Reddy’s Laboratories Ltd ADR
Exchange NYSE | Headquaters - | ||
IPO Launch date 2001-04-11 | CEO & Member of the Management Council Mr. Erez Israeli M.B.A. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 27811 | Website https://www.drreddys.com |
Full time employees 27811 | Website https://www.drreddys.com | ||
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.